Remington-Davis, Inc. — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$445,998	10
2024	Research	$163,871	10
2023	Research	$144,689	13
2022	Research	$122,218	13
2021	Research	$55,989	3
2020	Research	$60,166	2
2019	Research	$565,507	50

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $717,777 25 payments
Ironwood Pharmaceuticals, Inc $435,370 40 payments
Mylan Specialty L.P. $275,112 25 payments
Hikma Pharmaceuticals USA $123,386 8 payments
Chiesi USA, Inc. $6,750 2 payments
Merck Sharp & Dohme Corporation $43 1 payment

Studies the money was for Research payments · program years 2019–2025

C3718-302 $265,540 13 payments
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity Or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (Attain-Hypertension). Isas-Gzl1;Gzl2 $226,391 2 payments
A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $154,816 3 payments
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $144,646 12 payments
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $108,347 11 payments
McP-103-312 $74,531 14 payments
McP-103-205 $73,988 8 payments
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Atopic Dermatitis $73,389 4 payments
A Study of Ly3972406 in Adult Participants With Moderate-To-Severe Plaque Psoriasis $65,956 4 payments
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Ly3471851 in Patients With Psoriasis $61,093 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.